Coexisting autoimmune disorders among patients with inflammatory bowel disease at a tertiary center in Saudi Arabia: A cross-sectional study [0.03%]
沙特阿拉伯三级医疗中心炎症性肠病患者的共存自身免疫性疾病：一项横断面研究
Ahmed G Alghamdi,Aisha M Alanazi,Anas Z Nourelden et al.
Ahmed G Alghamdi et al.
Background: Approximately 25% of individuals with inflammatory bowel disease (IBD) concurrently experience immune-mediated inflammatory diseases (IMIDs), while the overall prevalence of these conditions in the general pop...
Comparison of long-term outcomes of infliximab and adalimumab therapy in biologic-naive patients with ulcerative colitis [0.03%]
初治溃疡性结肠炎患者接受英夫利昔α和阿达木单抗治疗的长期结局比较
Muhammed B Durak,Yavuz Cagir,Ilhami Yuksel
Muhammed B Durak
Background: To compare the long-term safety and efficacy of Adalimumab (ADA) and Infliximab (IFX) agents in biologic-naive patients with Ulcerative colitis (UC). ...
A bibliometric analysis of inflammatory bowel disease research in the Arab world [0.03%]
阿拉伯世界炎症性肠病研究的文献计量分析
Shadan AlMuhaidib,Khalid Bzeizi,Turki AlAmeel et al.
Shadan AlMuhaidib et al.
Background: The prevalence of inflammatory bowel disease (IBD) continues to increase worldwide, including in the Arab world. This study investigates IBD research output in Arab countries from 2009 to 2023, alongside preva...
Saleh A Alqahtani,Faisal M Sanai,Mohammed A Banama et al.
Saleh A Alqahtani et al.
Hepatitis D virus (HDV) prevalence data and country-specific HDV guidelines are not widely available in the Gulf Cooperation Council (GCC) states. We developed consensus recommendations to guide healthcare professionals, policymakers, and r...
Editorial: The safety and efficacy of ustekinumab in anti-TNFα refractory pediatric inflammatory bowel disease [0.03%]
述评：Ustekinumab治疗抗TNFα抗体无效的儿童炎症性肠病的安全性和有效性
Katelynn K Ho,David L Suskind,Ghassan T Wahbeh
Katelynn K Ho
Gut fungal profile in new onset treatment-naïve ulcerative colitis in Saudi children [0.03%]
沙特儿童溃疡性结肠炎患者发病时肠道真菌谱特征分析
Mohammad El Mouzan,Abdulaziz Al Quorain,Asaad Assiri et al.
Mohammad El Mouzan et al.
Background: Although the role of fungi in gut inflammation in IBD has been suggested, data are still limited in ulcerative colitis (UC). Our aim was to describe the gut fungal profile in a pediatric UC in Saudi Arabia. ...
The treatment naïve microbiome of pediatric ulcerative colitis and microbial therapeutics: A humbling challenge [0.03%]
初治儿童溃疡性结肠炎患者的肠道微生物组及微生物疗法：一个令人谦卑的挑战
Richard Kellermayer
Richard Kellermayer
Comparison of the effect of self-care education with two methods, teach-back and smartphone application, on the adherence to treatment in patients with inflammatory bowel disease [0.03%]
两种自我管理教育方法依从治疗的对照研究-重复教授法和智能手机应用程序在炎症性肠病患者中的效果比较研究
Zahra Sadat Manzari,Mohammad Sajjad Ghaderi,Hassan Vossoughinia et al.
Zahra Sadat Manzari et al.
Background: Self-care is one of the basic principles in the management of chronic diseases, which influences follow-up and adherence to treatment. Therefore, the current study was conducted with the aim of comparing the e...
Mohammed A Alzahrani,Edoardo V Savarino
Mohammed A Alzahrani
The effectiveness of vedolizumab in advanced therapy-experienced ulcerative colitis patients: Real world data from the Inflammatory Bowel Disease of the Middle East (IBD-ME) Registry group [0.03%]
维多珠单抗在使用过诱导疗法的重度溃疡性结肠炎患者中的疗效：中东炎症性肠病（IBD-ME）登记处的真实世界数据
Nahla Azzam,Othman Alharbi,Mansour Altuwaijri et al.
Nahla Azzam et al.
Background: Vedolizumab is an approved ulcerative colitis (UC) treatment. Multiple large randomized clinical trials have demonstrated the drug's efficacy and safety. However, real-world data from Middle Eastern countries ...